GILEAD SCIENCES, INC. — Director's Dealing 2013

Mar 6, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GILEAD SCIENCES INC (GILD)
CIK: 0000882095
Period of Report: 2013-03-04

Reporting Person: Washington Robin L (SVP, CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-03-04	Common Stock	M	4800	$23.755	Acquired	28594	Direct
2013-03-04	Common Stock	M	5000	$23.60	Acquired	33594	Direct
2013-03-04	Common Stock	S	9800	$43.6784	Disposed	23794	Direct
2013-03-05	Common Stock	M	45000	$24.295	Acquired	68794	Direct
2013-03-05	Common Stock	S	45000	$44.41	Disposed	23794	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2013-03-04	Non-Qualified Stock Option (right to buy)	$23.60	M	5000	Disposed	2019-01-21	Common Stock (5000)	Direct
2013-03-04	Non-Qualified Stock Option (right to buy)	$23.755	M	4800	Disposed	2020-01-28	Common Stock (4800)	Direct
2013-03-05	Non-Qualified Stock Option (right to buy)	$24.295	M	45000	Disposed	2022-01-26	Common Stock (45000)	Direct

Footnotes

F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.

F2: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.

F3: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F4: Sale prices reported for the transactions reported here range from $43.60 to $43.76. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

F5: Amount of securities beneficially owned following the reported transaction includes 968 shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan on February 15, 2013.